

National Imaging Associates, Inc.*	
Clinical guideline: BRACHYTHERAPY (Low Dose Radiation (LDR), High Dose Radiation (HDR), Selective Internal Radiation Therapy (SIRT, Electronic Brachytherapy)	Original Date: November 2013
CPT Codes: LDR: 77761, 77762, 77763, 77778, 77789 HDR: 77767, 77768, 77770, 77771, 77772 Electronic Brachytherapy: 0394T, 0395T	Last Revised Date: February 2021
Guideline Number: NIA_CG_224 - 1	Implementation Date: January 2022

Most requests for radiation therapy are addressed by NIA treatment site clinical guidelines. However, there may be requests that are not. For such requests, determinations will be made on a case-by-case basis utilizing the following guidelines (when applicable) but not limited to: National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology ASTRO (i.e., Model Policies; Evidence-Based Consensus Statement), ACR Appropriateness Criteria, American Society of Clinical Oncology (ASCO) and/or peer reviewed literature.

This guideline applies to other cancers not addressed by NIA treatment site clinical guidelines LDR (low dose rate brachytherapy) and HDR (high dose rate brachytherapy) must be requested separately and are not interchangeable.

Refer to applicable treatment site-specific guidelines for the management of primary malignancies. Applicable site-specific guidelines may include all or some of the sites below, depending on the specific program.

- Anal Cancer
- Bone Metastases
- Breast Cancer
- Cervical Cancer
- CNS Cancer
- Colon Cancer
- Rectal Cancer
- Endometrial Cancer
- Gastric Cancers
- Head and Neck Cancer
- Lung – Non-Small Cell
- Lung - Small Cell Lung Cancer
- Lymphoma - Hodgkin’s Lymphoma
- Lymphoma – Non-Hodgkin’s Lymphoma
- Pancreas Cancer
- Prostate Cancers

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

For metastasis to the brain, regardless of primary site, refer to the NIA clinical guideline for Central Nervous System (CNS). For metastasis to bone, refer to the NIA clinical guideline for Bone Metastases. For all other metastases, refer to the NIA clinical guideline for Metastatic Disease.

TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW

- Brachytherapy for sites beyond those listed above may be approvable with submission of supportive documentation (ASTRO, 2012).
- Intracavitary balloon catheter brain brachytherapy for malignant gliomas or metastasis to the brain is considered *investigational*.
- Selective Internal Radiation Therapy (SIRT), also known as radioembolization with microsphere brachytherapy device (RMBD) and transarterial radioembolization, uses microscopic radioactive spheres to deliver radiation to the tumor site. Treatment is delivered through catheter injection of radioactive Yttrium-90 (90Y) microspheres into the hepatic artery. Indications for SIRT include:
 - Unresectable metastatic liver tumors – see “**Metastatic Disease Guideline**”
 - Unresectable metastatic liver tumors from primary colorectal cancer see “**Metastatic Disease Guideline**”
 - Unresectable primary hepatocellular carcinoma (ACR, 2015)
 - Unresectable neuroendocrine tumors
- The use of electronic brachytherapy for basal cell and squamous cell cancers of the skin (of non-melanomatous skin cancers) and benign skin conditions are considered investigational and experimental at this time.
- Coronary Artery Brachytherapy (Negi,2016; Ohri, 2016; Oliver, 2008)
 - Intravascular Brachytherapy for coronary arteries is medically necessary when used as an adjunct to percutaneous coronary intervention for treatment of in-stent restenosis in a native coronary artery bare-metal stent or for drug-eluting stent
 - All other uses of brachytherapy for coronary arteries is considered investigational

POLICY HISTORY

Date	Summary
February 2021	Added <ul style="list-style-type: none"> • Coronary Artery Brachytherapy (Negi,2016; Ohri N, et.al 2016; Oliver, et al 2008) <ul style="list-style-type: none"> ○ Intravascular Brachytherapy for coronary arteries is medically necessary when used as an adjunct to percutaneous coronary

	<p>intervention for treatment of in-stent restenosis in a native coronary artery bare-metal stent or for drug-eluting stent</p> <ul style="list-style-type: none"> ○ All other uses of brachytherapy for coronary arteries is considered investigational <ul style="list-style-type: none"> • Added References
February 2020	Updated references
February 2019	Added and updated references

REFERENCES

- American Brachytherapy Society (ABS). Consensus Statement for Accelerated Partial Breast Irradiation. https://www.americanbrachytherapy.org/guidelines/Guidelines_Accelerated_Partial_Breast_Irradiation.pdf. Published 2013. Accessed April 24, 2018.
- American Brachytherapy Society (ABS) - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. http://www.americanbrachytherapy.org/guidelines/plaque_brachytherapy_melanoma_retinoblastoma.pdf. Published 2013.
- American College of Radiology (ACR). ACR Appropriateness Criteria®. Radiologic Management of Hepatic Malignancy. 2015.
- American College of Radiology (ACR) - SIR Practice Parameter for Radioembolization with Microsphere Brachytherapy Device (RMBD) for Treatment of Liver Malignancies. <http://www.acr.org/~media/d8086059b5f541e9b64e55d68a71693b.pdf>. Published 2014. Accessed on April 21, 2016.
- American Society for Radiation Oncology (ASTRO). Brachytherapy Model Policy. https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/BrachyMP.pdf. Published December 21, 2012. Accessed on May 12, 2017.
- Beriwal S, Demanes DJ, Erickson B, et al. American Brachytherapy Society Consensus Guidelines for Interstitial Brachytherapy for Vaginal Cancer. http://www.americanbrachytherapy.org/guidelines/Guidelines_Interstitial.pdf. Published 2012.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. *Hepatology*. 2011; 53(3):1020-1022. doi: 10.1002/hep.24199.
- Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol*. December 2006; 124(12):1684-1693. <http://www.ncbi.nlm.nih.gov/pubmed/17159027>.
- Crook JM, Haie-Meder C, Demanes DJ, et al. American Brachytherapy Society Consensus Statement for Penile Brachytherapy. http://www.americanbrachytherapy.org/guidelines/Guidelines_PenileBrachy.pdf. Published 2013.
- Davis BJ, Horwitz EM, Lee R, et al. American Brachytherapy Society Consensus Guidelines for Transrectal Ultrasound Guided Permanent Prostate Brachytherapy. http://www.americanbrachytherapy.org/guidelines/Guidelines_Transrectal_Ultrasound.pdf. Published 2012.

Holloway CL, DeLaney TF, Alektiar KM, et al. American Brachytherapy Society (ABS) Consensus Statement for Sarcoma Brachytherapy. http://www.americanbrachytherapy.org/guidelines/Guidelines_SarcomaBrachy.pdf. Published 2013.

Hsu I, Yamada Y, Vigneault E, et al. American Brachytherapy Society. Prostate High-Dose Rate Task Group. <http://www.americanbrachytherapy.org/guidelines/HDRTaskGroup.pdf>. Published 2008.

Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys*. 2007; 68(1):13-23. <http://www.ncbi.nlm.nih.gov/pubmed/17448867>.

Lee LJ, Das IJ, Higgins SA, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III. Low dose rate and pulsed-dose-rate brachytherapy. https://www.americanbrachytherapy.org/guidelines/Guidelines_Carcinoma_Cervix_PartIII.pdf. Published 2012.

Negi SI, Torguson R, Gai J, et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. *JACC Cardiovasc Interv*. 2016 Jun; 9(12):1259-1265.

Ohri N, Sharma S, Kini A, et al. Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents. *Adv Radiat Oncol*. 2016;1(1):4-9. doi:10.1016/j.adro.2015.12.002.

Oliver LN, Buttner PG, Hobson H, Golledge J. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. *Int J Cardiol*. 2008;126(2):216-223. doi:10.1016/j.ijcard.2007.03.132.

Park CC, Yom SS, Podgorsak MB, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) Emerging Technology Committee report on electronic brachytherapy. *Int J Radiat Oncol Biol Phys*. March 15, 2010; 76(4):963-972. <http://www.ncbi.nlm.nih.gov/pubmed/20206016>.

Small W, Beriwal S, Demanes DJ, et al. The American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. http://www.americanbrachytherapy.org/guidelines/Guidelines_Hysterectomy.pdf. Published 2012.

Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II. High dose brachytherapy. https://www.americanbrachytherapy.org/guidelines/Guidelines_Carcinoma_Cervix_PartII.pdf. Published 2012a.

Viswanathan AN, Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I. General principles. https://www.americanbrachytherapy.org/guidelines/Guidelines_Carcinoma_Cervix_Part1.pdf. Published 2012b.

Waksman R, Ajani AE, White RL, et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. *N Engl J Med*. 2002 Apr 18; 346(16):1194-1199.

Waksman R, Ajani AE, White RL, et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. *Circulation*. 2004 Jan 27; 109(3):340-344.

Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. *Lancet*. 2002 Feb 16; 359(9306):551-557.

Yamada Y, Rogers L, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.

http://www.americanbrachytherapy.org/guidelines/Guidelines_High-Dose-Rate_Prostate.pdf.

Published 2012.

Reviewed / Approved by NIA Clinical Guideline Committee

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.